Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options
If you purchased or acquired Ardelyx (NASDAQ: ARDX) securities between January 13, 2025 and August 6, 2026 (the “Class Period”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[Click here for additional information about the Ardelyx class action lawsuit]
Faruqi & Faruqi, LLP reminds investors in Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The firm is also investigating potential claims against Ardelyx.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116726073/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, and more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment.
On August 6, 2026, Ardelyx issued a press release announcing a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction to significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections.
On this news, the price of Ardelyx’s common stock declined dramatically. From a closing market price of $4.87 per share on August 6, 2026, Ardelyx’s stock price fell to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardelyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Ardelyx class action, go to www.faruqilaw.com/ARDX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions About the Ardelyx (NASDAQ: ARDX) Securities Class Action Lawsuit
What is the Ardelyx securities class action lawsuit about?
The Ardelyx securities class action alleges that Ardelyx, Inc. (NASDAQ: ARDX) misled investors about the commercial performance and growth prospects of XPHOZAH and IBSRELA and failed to disclose increasing payer-related access and reimbursement barriers that slowed new-patient starts.
Who is eligible to participate in the Ardelyx class action, and what is the Class Period?
Investors who purchased or acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between January 13, 2025 and August 6, 2026 (the Class Period) may be eligible if they suffered losses.
What is the lead plaintiff deadline in the Ardelyx class action?
The deadline to ask the court for appointment as lead plaintiff in the Ardelyx securities class action is November 16, 2026.
How much did Ardelyx stock drop?
Ardelyx’s stock price fell from a closing price of $4.87 per share on August 6, 2026 to $4.00 per share on August 7, 2026, a decline of about 18%.
What is a lead plaintiff, and do I need to be one to share in a recovery?
A lead plaintiff represents the proposed class and directs and oversees the litigation. Investors seeking appointment must file a motion with the court by November 16, 2026. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Why should Ardelyx investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Ardelyx securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation by calling Josh Wilson at 877-247-4292 or visiting www.faruqilaw.com/ARDX.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116726073/en/
Contacts
Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)